At the 62nd EASD in Milan, Sinocare showcased a suite of connected health solutions poised to revolutionise chronic disease care across home, pharmacy and hospital settings, emphasising digital integration and AI-driven analytics.
Sinocare used the 62nd annual meeting of the European Association for the Study of Diabetes in Milan to promote a range of connected tools for chronic disease management, positioning the event as part of a wider push into digital care across home, pharmacy and hospital settings. The company said its portfolio is intended to support patients from initial risk screening through to day-to-day monitoring and longer-term management.
At the home-care end of the range, Sinocare highlighted the Safe AQ max II blood glucose monitor, which it says returns a reading in five seconds and can sync data by Bluetooth. It also showcased the KUG-11 device, which measures glucose, uric acid and ketones, alongside a veterinary monitor aimed at diabetes care for dogs and cats. In Milan, the company framed these products as part of a broader connected care model, echoing earlier presentations at China’s CMEF and the International Diabetes Federation conference, where it emphasised continuous glucose monitoring and digital analytics.
For community pharmacies, Sinocare pointed to the iCARE-1300 portable analyser, which it says can test close to 100 measures, including blood glucose, lipids, HbA1c and kidney function markers, with results in minutes. The firm also described a pharmacy-based “Health Station” model designed to extend screening and risk assessment beyond the clinic. In hospitals, it promoted the AGEscan device for non-invasive screening of advanced glycation end products, as well as a blood glucose management system that links to hospital information systems and combines meter and continuous glucose monitoring data for bedside use.
Sinocare’s broader pitch is that its technologies can knit together screening, monitoring and care management across different settings. That message fits with the company’s recent public appearances, where it has stressed artificial intelligence, biosensors and data connectivity as the basis of its product strategy. The company says it serves more than 25 million users in 187 countries and ranks among the world’s largest blood glucose meter makers, but the Milan presentation was focused less on market share than on showing how it wants to position itself in the expanding digital diabetes care market.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
